International Federation of Inventors’ Associations (IFIA) becomes the partner of the Pharma & Biotech IP USA 2020.
The life sciences are in a period of dramatic change and innovation. Developments in new technologies, such as cell therapies and gene editing, are challenging traditional IP strategies and business models.
IAM’s fourth annual Pharma and Biotech IP will bring together leading in-house practitioners and expert counsel to discuss next-generation strategies for protecting and exploiting cutting-edge innovation.
IAM is the leading intelligence platform for the global IP market. Our unrivaled coverage and in-depth analysis of key sectors give our clients critical information to enable them to maximize the value of their IP assets.
Our unique and timely intelligence, analysis and data service informs high-level corporate decision making, while our extensive connections with senior operators in the corporate, legal, policymaking, and investment worlds provide a clear line of sight into market developments before they are widely known.
IAM offers global coverage of the IP value creation environment. Our worldwide team of reporters, researchers, and analysts provide an unmatched understanding of local markets in North America, Europe, and Asia to ensure that IAM is the first to provide the analysis that matters.
Pharma & Biotech IP USA 2020
October 8, 2020
The life sciences are seeing developments in new technologies and undergoing a period of dramatic change and innovation, all of which are challenging traditional IP strategies and business models.
Next-generation strategy for cutting-edge innovation
IAM’s inaugural Pharma & Biotech IP USA heads to Boston after four successful years in Europe to bring together leading in-house practitioners and expert counsel to explore next-generation strategies for protecting and exploiting cutting-edge innovation.
Visit the website and use code* IFIA10 when you register to save 10%!
*Valid for registrations made on or after May 7, 2020.